Background-At one end of the clinical spectrum of coronary artery disease (CAD) are subjects who have had repeated acute ischemic events, and at the other end are those with long-standing angina who have never been unstable. This study tests the hypothesis that a specific biological profile can distinguish these 2 extreme groups and predict acute coronary events. Methods and Results-Blood levels of lipoprotein(a), homocysteine, tissue plasminogen activator, plasminogen activator inhibitor-1, C-reactive protein (CRP), fibrinogen, and von Willebrand factor were compared in 3 groups of 50 subjects each: (1) those with previous multiple acute coronary events, (2) age-matched subjects with Ն3 years of stable angina and no prior acute coronary events, and (3) matched controls without evidence of atherosclerotic disease and a normal coronary angiogram. All subjects were followed for 4.0 years. Lipoprotein(a), homocysteine, tissue plasminogen activator, and plasminogen activator inhibitor-1 were similar in both CAD groups and significantly higher than in the control group. However, compared with subjects with long-standing stable angina, those with previous multiple coronary events had higher values of CRP (5.7Ϯ5. 
C linicians have often been intrigued that among patients with coronary artery disease (CAD), some have recurrent acute coronary events, such as myocardial infarction (MI) and unstable angina (UA), whereas others have effortinduced angina and remain clinically stable for many years. 1, 2 The pathophysiological substrate of acute CAD is believed to be an inflamed and fissured or eroded atherosclerotic plaque with superimposed platelet aggregation and thrombus formation. 3, 4 Therefore, a background procoagulant or proinflammatory state and/or a specific metabolic profile could predispose an individual to acute coronary events. Epidemiological and cross-sectional studies have shown that a number of thrombogenic, inflammatory, and metabolic markers are associated with atherosclerosis, CAD, and MI. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] However, it is uncertain whether these are markers for the presence and extent of atherosclerosis or whether they reflect a particular susceptibility to acute coronary events. 24 Thus, it is unclear whether acute CAD is a random event on a varying background of coronary atherosclerosis, is a direct function of the extent of the coronary atherosclerotic burden, and/or is modulated by specific biological risk factors. 3, 24, 25 One means of gaining more insight into this question is to study patients at the extremes of the clinical spectrum of CAD: on one hand, those with a history of multiple acute coronary events, and on the other hand, those with long-standing angina who have never been clinically unstable even though they generally have diffuse CAD. 2 We sought to determine whether, in these clinical subsets and in a control group with a normal coronary angiogram, there exist differences in biological markers known to be associated with CAD. These groups were then followed for 4 years to examine the relation of these baseline markers with the occurrence of new acute coronary events.
Methods

Patients
Eligible subjects were identified by scanning consecutive discharge summaries of patients hospitalized with a diagnosis of MI or UA and by scanning the notes of consecutive patients seen at the cardiac outpatient clinic or undergoing coronary arteriography. Three groups of 50 subjects each were established in 1995 to 1996, characterized, and prospectively followed.
Group With Multiple Acute Coronary Events
Patients with multiple acute coronary events (MACE) had either Ն3 MIs or Ն4 acute coronary events (MI or UA) with at least 1 MI. The diagnosis of MI required characteristic prolonged (Ն30-minute) symptoms and creatine kinase elevation more than twice the upper normal limit (or creatine kinase-MB Ն10 U/L or Ն5% of total creatine kinase). UA was defined as characteristic symptoms, either new in onset or a sharp and significant change in the pattern of established angina, appearing at rest or on minimum exertion and requiring hospitalization. Men had to be aged Ͻ60 years and women had to be aged Ͻ65 years at the time of their first coronary event, and all subjects had to be aged Ͻ70 years at the time of blood sampling of the biological markers to avoid the possibly confounding effect of excessive age. There had to be Ն1 month between acute coronary events for both to be counted. Those occurring within 6 months of a revascularization procedure were not considered. The last acute coronary event had to have occurred Ͼ3 months before blood sampling.
Group With SA
The patients with stable angina (SA), age-matched with the multiple events group, had to have a minimum 3-year history of stable angina without any episode suggestive of acute CAD, confirmed by specific questioning. CAD had to be documented by arteriography showing stenosis Ն70% of at least 1 major epicardial artery. These patients had to have a normal ECG, except for possible minor nonspecific ST-T features, and documented normal left ventricular contractility.
Control Group
These subjects, matched for age and sex with MACE patients, had to have a coronary angiogram, performed within 3 years of blood sampling, judged unequivocally normal by 3 experienced observers. In 39 subjects, the angiogram was performed to rule out CAD, and in 11 subjects, it was performed before replacement of a stenotic aortic valve by a bioprosthesis. All control subjects were required to have no clinical evidence of atherosclerotic disease in other vascular beds.
Excluded from the present study were subjects taking steroid/ immunosuppressive drugs or who had type 1 diabetes, tendinous xanthomas, or any clinically significant disease or history of cancer, unless it was considered to have been cured for Ն5 years. At the time of blood sampling, there had to be no ongoing or recent (Ͻ1 month) inflammatory or infectious disease, no surgical procedure or angioplasty in the preceding 3 months, and no arteriography in the preceding month.
The study was approved by the hospital ethics committee, and all subjects gave informed consent.
Blood Biological Markers
Blood sampling was carried out in patients after a 15-minute rest in the supine position between 7:00 and 9:00 AM after a 12-hour fast with no alcohol intake in the previous 48 hours and no tobacco use that morning.
Factors measured and methods used were as follows: total cholesterol, HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), apolipoprotein B (apoB), triglycerides, lipoprotein(a) [Lp(a)], and homocysteine, measured by use of methods previously described 24, 26 ; C-reactive protein (CRP), measured by the N Latex CRP monoassay using a nephelometric technique (interassay reproducibility 3.6% to 4.4%, assay range 0.18 to 1100 mg/L, and sensitivity 0.18 mg/L) with a Behring Nephelometer 100 Analyzer (Dade Behring); and fibrinogen, von Willebrand factor antigen (vWF), tissue plasminogen activator antigen (tPA), and plasminogen activator inhibitor-1 antigen (PAI-1), measured as previously described. 24 Intra-assay and interassay variabilities for vWF, tPA, and PAI-1 were 8% and 10%, respectively.
Follow-Up
All subjects were followed for 4.0 years. The events during follow-up, MI (fatal and nonfatal), and UA, as defined above, were considered in the primary analysis. Secondary analyses examined the relation of baseline measures to composites of (1) cardiac death, MI, and UA, (2) all-cause death, MI, and UA, and (3) cardiac death and MI.
Statistical Analysis
Values are expressed as meanϮSD or as medians with 25% to 75% interquartile ranges, as appropriate. For continuous variables, comparisons among the 3 groups were performed by using 1-way ANOVA. Categorical variables were analyzed by using the Fisher exact test. Biological variables distinguishing the 2 CAD groups were analyzed, after rank transformation, by using a multivariate ANCOVA with potentially confounding factors as covariates; results were reported as unadjusted means. In follow-up analysis, continuous variables were compared by using the Student t test or Wilcoxon rank sum test as appropriate. The Fisher exact test was used for categorical data. A multivariate logistic regression analysis was performed to identify discriminant predictive parameters. All tests were 2-tailed, and probability values were considered significant at the 0.05 level.
Results
Baseline Clinical Profile
Over two thirds of the 50 subjects with MACE had a history of Ն3 MIs, and nearly half had a history of Ն5 acute events. All but 1 had sustained their last acute event despite aspirin and/or coumadin therapy. There was no clustering of events in the year before blood sampling. Of a total of 237 prior acute coronary events in these subjects, 15 (6.3%) occurred in the 12 months before blood sampling. The last event before blood sampling occurred 1.8Ϯ1.4 years previously. The SA group had a history of angina for 9Ϯ5 years. Seven (14%) SA patients and 27 (54%) MACE patients had undergone a percutaneous revascularization procedure, whereas 23 (46%) SA patients and 28 (56%) MACE patients had undergone coronary artery bypass surgery. Table 1 summarizes clinical and some laboratory characteristics. In the MACE group, left ventricular ejection fraction was Ն50% in 25 subjects, 40% to 49% in 8 subjects, 30% to 39% in 10 subjects, and Ͻ30% in 7 subjects. By study criteria, SA and control subjects had normal left ventricular function. Although insulin was being used by 7 MACE subjects and by 1 SA subject (Pϭ0.06), glucometabolic control was not significantly different in diabetic subjects in the MACE group compared with the SA group. In the MACE group versus the SA group, glycated hemoglobin was 7.0Ϯ2.0% versus 5.9Ϯ2.0% (Pϭ0.2), respectively, and serum fructosamine (reflecting glycemic control over the pre-vious 2 to 3 weeks) was 277.5Ϯ70.4 versus 270.9Ϯ57.7 mol/L (Pϭ0.8), respectively.
Biological Markers
Lp(a), homocysteine, tPA, and PAI-1 were markedly raised in both CAD groups compared with the control group but were not significantly different in the MACE group compared with the SA group (Table 2) . However, CRP was significantly raised in the MACE group compared with the SA group (5.7Ϯ5.4 versus 3.0Ϯ5.2 mg/L, respectively; Pϭ0.012), as was fibrinogen (3.38Ϯ0.75 versus 2.92Ϯ0.64 g/L, respectively; Pϭ0.001) and vWF (1.60Ϯ0.55 versus 1.25Ϯ0.36 U/mL, respectively; Pϭ0.0003) (Figure 1 ). These latter 3 markers were not significantly different in the SA group compared with the control group. In a multivariate analysis, this triad was significantly raised in the MACE group compared with the SA group (PϽ0.0001) and remained so after controlling for the potentially confounding factors of current smoking, diabetes, HDL-C, use of ACE inhibitors and coumadin, presence of noncardiac vascular disease, and left ventricular ejection fraction Ͻ40% (Pϭ0.02).
Follow-Up
MI and UA occurred in 42% of the group with MACE (8 MIs, 13 UA episodes), in 4% of the group with SA (2 UA episodes) (PϽ0.0001), and in no subject in the control group. Time to first occurrence was 1.6Ϯ1.2 years. Of the 15 UA episodes, 6 episodes (40%) were accompanied by acute transient ST-T changes (with raised serum cardiac markers in 2), and in 3 episodes (20%), cardiac markers were raised without ECG changes. In the 50 subjects with MACE, there were 14 deaths (28%), of which 11 were cardiac-related; 3 of the latter were fatal MIs, 2 were sudden deaths, and 6 were due to heart failure. In the group with SA, the only death was not cardiac-related. There were no deaths in the control group. In the 100 subjects with CAD, of all baseline clinical and biological variables, CRP was the most powerful predictor for distinguishing those with from those without subsequent acute coronary events, with a median value 2.7 times higher for those with events (Table 3) . Other variables significantly associated with follow-up coronary instability were current smoking at baseline, use of ACE inhibitors and coumadin, total cholesterol/HDL-C ratio, apoB, LDL-C, and fibrinogen. After controlling for these variables and for left ventricular ejection fraction Ͻ40% and use of lipid-lowering and antiplatelet agents, only CRP (adjusted odds ratio 5.7, 95% CI 1.9 to 17.2; Pϭ0.002) and current smoking status (adjusted odds ratio 3.3, 95% CI 1.1 to 9.5; Pϭ0.03) distinguished those with follow-up acute coronary events. Each 1 mg/L rise in baseline CRP was associated with a relative risk of 1.2 (95% CI 1.0 to 1.3, Pϭ0.009) for follow-up coronary instability. A CRP value Ͼ3.5 mg/L was associated with a relative risk of 7.6 (95% CI 2.6 to 21.7, Pϭ0.0002) for subsequent acute coronary events. This CRP cutoff value identified 17 of the 23 subjects who had acute coronary events on follow-up (sensitivity 74%) and, in contrast, was found in 21 of the 77 subjects who did not become unstable (specificity 73%) (Figure 2) . Thus, over the 4-year follow-up, the positive predictive value was 48%, and the negative predictive value was 91%.
In secondary analyses, when cardiac death was included as a follow-up event, along with MI and UA, findings were similar. The 28 subjects with these new events had a CRP of 7.3Ϯ7.5 (median 4.5) mg/L compared with 3.2Ϯ3.9 (median 1.8) mg/L in the remaining 72 CAD subjects without an event (PϽ0.0001). Corresponding values for fibrinogen were 3.58Ϯ0.84 (median 3.51) g/L and 2.98Ϯ0.61 (median 2.94) g/L, respectively (PϽ0.0001). Corresponding values for vWF were not significantly different (1.53Ϯ0.54 versus 1.39Ϯ0.48 U/mL, Pϭ0.2). These findings were unchanged when allcause death was substituted for cardiac death. When the composite follow-up event was restricted to cardiac death and MI, the 16 subjects with this event had higher values of CRP, fibrinogen, and vWF than did the 84 CAD subjects without this event (Pϭ0.01, Pϭ0.03, and Pϭ0.03, respectively).
Discussion
The present prospective study examined 2 subsets of patients at the extremes of the spectrum of CAD, in addition to a control group with normal coronary arteries. At one end of the spectrum were patients with long-standing angina who had always been clinically stable; at the other end were patients who had sustained several acute coronary events. The principal findings are as follows: (1) CRP, fibrinogen, and vWF were significantly raised in the group with MACE compared with both SA and control groups, and this held true after controlling for potentially confounding factors. (2) The markers Lp(a), homocysteine, tPA, and PAI-1 were raised in both groups with CAD in contrast to the control group. (3) On follow-up, of all the biological variables, only CRP was a strong independent predictor of new acute coronary events that occurred preponderantly in the MACE group, whereas a lower CRP was a very good predictor of low risk. Thus, these findings suggest that within a population with coronary atherosclerosis, clinically stable at the time of blood sampling, those with a history of repeated acute coronary events have an inflammatory biological profile in contrast to CAD subjects who have always been stable. In addition, this profile identifies those at risk for subsequent acute coronary events. This finding also differs from a profile characterized by raised Lp(a), homocysteine, tPA, and PAI-1 that was comparable in both CAD subsets, in contrast to the control group, and was not predictive of subsequent coronary instability. These results are provocative insofar as they suggest a dichotomy between an acute/inflammatory profile and a chronic/atherogenic profile within the CAD population. They suggest that not all atherosclerosis is necessarily or equally inflammatory, raising the possibility that a more inflammatory expression of atherosclerosis in certain individuals with CAD may increase the risk of sustaining acute coronary events.
Previous Studies
Studies have suggested, in addition to classic risk factors, the existence of metabolic, hemostatic, and inflammatory risk markers for CAD. Relationships have been found in initially healthy subjects between raised baseline values of Lp(a), homocysteine, fibrinogen, CRP, and tPA and the risk of CAD. 6, 10, 15, 16, 22, 27 Other studies have associated baseline vWF, factor VIII, tPA, PAI-1, fibrinogen, CRP, and fibrin turnover with subsequent cardiac events in patients with initial angina, MI, or angiographic CAD. 5,7,9,11,14,17,23,28 With few exceptions, 11,28 these studies did not attempt to control for the presence and extent of atherosclerosis, so it is unclear whether these are markers of the latter or whether they indicate an additional specific vulnerability for the occurrence of acute coronary events on a common atherosclerotic background. 8,12,13,18 -21 More generally, this raises the question of whether a dichotomy between atherogenic and thrombogenic/inflammatory risk markers should be postulated. In a previous study, we found no differences between the biological profiles of subjects with SA and those with a single unheralded MI. 24 The 2 groups had different ages, there was no control group and no follow-up, and patients who have had a single MI may be quite different from those who have incurred several acute coronary events. The present study was undertaken because of these limitations.
CAD Groups Versus Control Group
It is intriguing that levels of fibrinogen, CRP, and vWF were not significantly different in the stable angina group compared with the control group. The latter did have a relatively important proportion of CAD risk factors, which may have raised some of the parameters evaluated. However, at least regarding fibrinogen, for which there is abundant published data, the control group of the present study had values within the range of the control cohorts, as previously reviewed. 29 Because it is likely that the SA group had diffuse coronary atherosclerosis 2, 30 (as in the MACE group, about half the SA group had previously undergone coronary artery bypass surgery) and because at least a third had manifest disease in other vascular beds, this suggests that the chronic inflammatory component of the atherosclerotic disease process might be less important in some subjects and much more intense in others. Thus, an enhanced inflammatory atherosclerosis, associated with plaques prone to instability in patients with previous MACE, may have rendered them particularly susceptible to acute coronary events, whereas a subdued inflammatory expression of atherosclerosis in patients with SA who had never been clinically unstable might explain their lesser vulnerability to acute coronary events. These very suggestive baseline findings were confirmed by the follow-up observa- tions, whereby increased CRP was a strong predictor of coronary instability, contrary to the postulated atherogenic factors, Lp(a), homocysteine, tPA, and PAI-1.
Study Limitations
Although subjects were well characterized and the follow-up event rate was high enough to draw statistically pertinent conclusions, study subsets were not large, and inherent to the methodological approach, they were highly selected. This must temper the interpretation of results. As with any clinical or biological risk marker, there was an inevitable overlap in CRP values between those with and without events despite relatively good predictive values. Therefore, findings must be seen as hypothesis-generating and require confirmation. The definition of UA both as a selection criteria and as a follow-up event, albeit a rigorous clinical definition, did not require ECG changes and/or positive serum markers. However, this definition was advantageous, because as applied to select the SA group, it allowed greater certainty of the absence of prior coronary instability. As for the MACE group, 68% had had at least 3 MIs, and an additional 28% had had 2 MIs as well as Ն2 UA episodes; only 2 subjects had 1 MI and Ն3 UA episodes. Thus, it is unlikely that the definition of UA used in the present study detracted from the constitution of a group of patients with a strong history of recurrent acute coronary insults. Finally, over half of the follow-up UA episodes did have acute ECG changes and/or raised serum markers. Detection of transient ECG changes would be less likely in many of these patients with severe CAD and left ventricular dysfunction, all of whom had an already perturbed baseline ECG.
Conclusions
An inflammatory biological risk profile was found in patients with a history of repeated acute coronary events. At the other extreme of the clinical spectrum of CAD, the present study identified a subset without an elevated inflammatory biological profile. This profile was found to strongly predict acute coronary instability on 4-year follow-up. These results are consistent with the presence of a smoldering subclinical inflammatory state in some subjects with CAD. This supports other lines of inquiry linking markers of inflammation to the risk of acute CAD and reinforces the rationale for the clinical use of inflammatory markers for identifying patient subsets at higher and lower risk for new and recurrent coronary instability. 23, [31] [32] [33] [34] In addition, the present study suggests a possible distinction between atherogenic markers, which were not significantly different at both ends of the CAD clinical spectrum and not predictive of new instability, in contrast to inflammatory markers, which were different and predictive. Future work should investigate why the inflammatory component seems less pronounced in some subjects with atherosclerosis and more intense in others, appearing to render them particularly vulnerable to acute coronary events.
